CAMBRIDGE, Mass.--(BUSINESS WIRE)--Ultivue has appointed Philippe Mourere as Senior Vice President, Commercial Operations. Mourere previously served as Vice President of Global Sales and Marketing at Cell Signaling Technology and as Senior Director, Corporate Development, Life Science & Technology Business at PerkinElmer, Inc. From 2006 to 2012, Mourere served as Senior Director, Global Sales & Marketing, Discovery, Alliances & Services and as Marketing Manager at Caliper Life Sciences, Inc., acquired by PerkinElmer for approximately $600 million in 2011. From 2002 to 2006, Mourere served as Sales Manager at CIS Bio International, acquired by Ion Beam Applications, S.A. in 2008.
“We are delighted to have Philippe join Ultivue’s Executive Management team to lead the commercialization of our reagent-based solutions for high definition biology,” said Dr. Michael Natan, Chief Executive Officer. “Philippe’s domain knowledge and business experience will accelerate the market introduction and broad adoption of our technology and offerings of reagents, instrumentation and strategic partnerships in the biomedical research and diagnostic community.”
Mourere received his M.Sc. in Molecular and Cell Biology from the University Paul Sabatier and his D.E.S.S. in Biology-Biotechnology from St. Jerome University, France.
Ultivue will present its most recent advances in biomarker multiplexing in tissue at the upcoming annual meeting conference of the American Association of Cancer Research (AACR) April 1-5 in Washington DC. “Ultivue’s unique value proposition that combines unlimited multiplexing in situ with high spatial resolution and pharma-friendly workflows will set a new standard for biomarker discovery. By facilitating the identification of clinically-relevant, highly-reproducible biomarker signatures using existing workflows, drug approval and companion diagnostic test development will be accelerated,” said Mourere.
Mourere added that “Ultivue will continue to build up on its recent, successful strategic engagements with pharmaceutical companies, expanding its commercial capabilities to reach the biotech and translational research communities.”
Founded by world-leading experts in biomolecular analysis, Ultivue is a venture-backed company developing reagent-driven solutions for high-definition biological imaging in situ, combining unlimited multiplexing at high speed with high spatial resolution. Ultivue’s proprietary reagents, instruments, and bioinformatics tools will enable researchers and clinicians to realize the promise of personalized medicine through better matching of patients to therapeutic options. In 2017, the company is launching products and services that seamlessly integrate into existing workflows for biomarker discovery, assay validation, and companion diagnostic applications. Ultivue is based in Cambridge, MA.
To learn more, visit www.ultivue.com